

Amalia Gastaldelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8423215/publications.pdf>

Version: 2024-02-01

407
papers

29,376
citations

5574

82
h-index

5988

160
g-index

419
all docs

419
docs citations

419
times ranked

27697
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 1388-1402.	3.7	3,403
2	A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2006, 355, 2297-2307.	27.0	1,584
3	Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993, 265, E380-E391.	3.5	956
4	Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease. <i>Nutrients</i> , 2013, 5, 1544-1560.	4.1	648
5	Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. <i>Diabetologia</i> , 2005, 48, 634-642.	6.3	642
6	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. <i>Gastroenterology</i> , 2007, 133, 496-506.	1.3	500
7	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2016, 59, 1121-1140.	6.3	485
8	Î²-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 493-500.	3.6	470
9	A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 2461-2474.	0.6	447
10	Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. <i>Trends in Molecular Medicine</i> , 2008, 14, 72-81.	6.7	381
11	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. <i>Obesity Facts</i> , 2016, 9, 65-90.	3.4	371
12	Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3498-3504.	3.6	370
13	The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. <i>Nutrients</i> , 2015, 7, 9453-9474.	4.1	354
14	Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients. <i>Diabetes</i> , 2008, 57, 1340-1348.	0.6	353
15	Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1389-1397.	7.3	348
16	Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. <i>Liver International</i> , 2011, 31, 1285-1297.	3.9	337
17	Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. <i>Hepatology</i> , 2009, 49, 1537-1544.	7.3	310
18	Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. <i>Hepatology</i> , 2018, 67, 145-158.	7.3	296

#	ARTICLE	IF	CITATIONS
19	Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1â€‘ Stimulated Postprandial Insulin Secretion in Humans. <i>Diabetes</i> , 2011, 60, 2308-2314.	0.6	294
20	Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. <i>Diabetologia</i> , 2004, 47, 31-39.	6.3	287
21	Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. <i>Diabetes</i> , 2000, 49, 1367-1373.	0.6	285
22	Meal and oral glucose tests for assessment of Î²-cell function: modeling analysis in normal subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E1159-E1166.	3.5	267
23	Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. <i>Diabetes Care</i> , 2018, 41, 1732-1739.	8.6	266
24	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.9	254
25	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. <i>JHEP Reports</i> , 2019, 1, 312-328.	4.9	251
26	Acute effects of gastric bypass versus gastric restrictive surgery on Î²-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. <i>International Journal of Obesity</i> , 2010, 34, 462-471.	3.4	242
27	Visceral Fat in Hypertension. <i>Hypertension</i> , 2004, 44, 127-133.	2.7	239
28	Metabolic Effects of Visceral Fat Accumulation in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5098-5103.	3.6	236
29	Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. <i>Diabetes</i> , 2017, 66, 815-822.	0.6	234
30	Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009, 50, 1087-1093.	7.3	231
31	Blockade of Glucagon-like Peptide 1 Receptor Corrects Postprandial Hypoglycemia After Gastric Bypass. <i>Gastroenterology</i> , 2014, 146, 669-680.e2.	1.3	229
32	Gastric bypass and banding equally improve insulin sensitivity and Î² cell function. <i>Journal of Clinical Investigation</i> , 2012, 122, 4667-4674.	8.2	222
33	Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity. <i>Circulation</i> , 2001, 103, 513-519.	1.6	209
34	Assessing Insulin Secretion by Modeling in Multiple-Meal Tests: Role of Potentiation. <i>Diabetes</i> , 2002, 51, S221-S226.	0.6	209
35	Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4628-4634.	3.6	204
36	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. <i>Hepatology</i> , 2008, 47, 746-754.	7.3	204

#	ARTICLE	IF	CITATIONS
37	Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. <i>Diabetologia</i> , 2011, 54, 2093-2102.	6.3	183
38	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 835-856.	17.8	183
39	Why does obesity cause diabetes?. <i>Cell Metabolism</i> , 2022, 34, 11-20.	16.2	183
40	Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1349-1357.	8.6	170
41	Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3270-H3278.	3.2	169
42	Thiazolidinediones improve β -cell function in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E871-E883.	3.5	167
43	Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats. <i>Hypertension</i> , 2009, 53, 508-515.	2.7	160
44	Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 393-406.	11.4	155
45	Insulin Resistance, Insulin Response, and Obesity as Indicators of Metabolic Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2885-2892.	3.6	149
46	Pancreatic islet amyloidosis, β -cell apoptosis, and β -cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13992-13997.	7.1	147
47	An accurate and robust method for unsupervised assessment of abdominal fat by MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 684-689.	3.4	140
48	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 697-706.	7.3	140
49	Ectopic fat and cardiovascular disease: What is the link?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 481-490.	2.6	139
50	Effect of Physiological Hyperinsulinemia on Gluconeogenesis in Nondiabetic Subjects and in Type 2 Diabetic Patients. <i>Diabetes</i> , 2001, 50, 1807-1812.	0.6	136
51	Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 104-111.	4.7	131
52	Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 1012-1021.	3.7	128
53	Pathophysiology of Non Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2082.	4.1	126
54	Pathophysiology of β -Prediabetes. <i>Medical Clinics of North America</i> , 2011, 95, 327-339.	2.5	124

#	ARTICLE	IF	CITATIONS
55	Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance. PLoS ONE, 2014, 9, e94059.	2.5	124
56	A new correction factor for use in tracer estimations of plasma fatty acid oxidation. American Journal of Physiology - Endocrinology and Metabolism, 1995, 269, E649-E656.	3.5	122
57	Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology, 2012, 55, 1406-1415.	7.3	118
58	Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia, 2013, 56, 156-161.	6.3	117
59	Insulin: new roles for an ancient hormone. European Journal of Clinical Investigation, 1999, 29, 842-852.	3.4	114
60	Beta-Cell Function in Obesity: Effects of Weight Loss. Diabetes, 2004, 53, S26-S33.	0.6	114
61	Liver Enzymes Are Associated With Hepatic Insulin Resistance, Insulin Secretion, and Glucagon Concentration in Healthy Men and Women. Diabetes, 2011, 60, 1660-1667.	0.6	112
62	Early Hypertension Is Associated With Reduced Regional Cardiac Function, Insulin Resistance, Epicardial, and Visceral Fat. Hypertension, 2008, 51, 282-288.	2.7	107
63	Altered Islet Function and Insulin Clearance Cause Hyperinsulinemia in Gastric Bypass Patients With Symptoms of Postprandial Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2008-2017.	3.6	107
64	Autonomic and Hemodynamic Responses to Insulin in Lean and Obese Humans. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2084-2090.	3.6	105
65	Pericardial Rather Than Epicardial Fat is a Cardiometabolic Risk Marker: An MRI vs Echo Study. Journal of the American Society of Echocardiography, 2011, 24, 1156-1162.	2.8	105
66	Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia, 2003, 46, 1211-1219.	6.3	103
67	Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3914-3921.	3.6	103
68	Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. Nature Communications, 2016, 7, 8994.	12.8	103
69	Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms. Current Diabetes Reports, 2015, 15, 607.	4.2	102
70	The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. Journal of Lipid Research, 2009, 50, 1293-1304.	4.2	100
71	Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver. Diabetes Care, 2013, 36, 2331-2338.	8.6	100
72	Long-Term Effects of Bariatric Surgery on Meal Disposal and β -Cell Function in Diabetic and Nondiabetic Patients. Diabetes, 2013, 62, 3709-3717.	0.6	98

#	ARTICLE	IF	CITATIONS
73	Pioglitazone in the treatment of NASH: the role of adiponectin. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 769-775.	3.7	97
74	Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. <i>Diabetes</i> , 1999, 48, 1258-1263.	0.6	96
75	Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2011, 93, S60-S65.	2.8	94
76	Mechanism and Effects of Glucose Absorption during an Oral Glucose Tolerance Test Among Females and Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 515-524.	3.6	92
77	Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2818-2826.	3.6	91
78	Autonomic and Hemodynamic Responses to Insulin in Lean and Obese Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2084-2090.	3.6	90
79	Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E1775-E1781.	3.5	89
80	̑-Cell Function in Morbidly Obese Subjects During Free Living: Long-Term Effects of Weight Loss. <i>Diabetes</i> , 2005, 54, 2382-2389.	0.6	88
81	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 88-103.	7.1	88
82	Fat metabolism during high-intensity exercise in endurance-trained and untrained men. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 122-128.	3.4	87
83	Effects of Probiotic Supplementation on Gastrointestinal, Sensory and Core Symptoms in Autism Spectrum Disorders: A Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 550593.	2.6	86
84	Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. <i>Diabetic Medicine</i> , 2012, 29, 622-627.	2.3	85
85	Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. <i>Diabetologia</i> , 2017, 60, 1873-1882.	6.3	85
86	Prevention of Diabetes With Pioglitazone in ACT NOW. <i>Diabetes</i> , 2013, 62, 3920-3926.	0.6	83
87	Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 278, E794-E801.	3.5	82
88	Pathway of free fatty acid oxidation in human subjects. Implications for tracer studies.. <i>Journal of Clinical Investigation</i> , 1995, 95, 278-284.	8.2	82
89	Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 275-281.	4.7	80
90	Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?. <i>Clinical Science</i> , 2017, 131, 2701-2704.	4.3	80

#	ARTICLE	IF	CITATIONS
91	Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 526-535.	3.7	80
92	Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 29, 677-684.	3.4	79
93	Splanchnic and leg substrate exchange after ingestion of a natural mixed meal in humans. <i>Diabetes</i> , 1999, 48, 958-966.	0.6	78
94	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. <i>Hepatology</i> , 2016, 64, 2028-2037.	7.3	78
95	Insulin: The master regulator of glucose metabolism. <i>Metabolism: Clinical and Experimental</i> , 2022, 129, 155142.	3.4	78
96	Effect of Acute Hyperglycemia on Insulin Secretion in Humans. <i>Diabetes</i> , 2002, 51, S130-S133.	0.6	77
97	The Effect of Pioglitazone on the Liver: Role of adiponectin. <i>Diabetes Care</i> , 2006, 29, 2275-2281.	8.6	76
98	Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. <i>Diabetologia</i> , 2007, 50, 1500-1508.	6.3	76
99	The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention. <i>Current Vascular Pharmacology</i> , 2008, 6, 301-312.	1.7	76
100	HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH. <i>PLoS ONE</i> , 2014, 9, e97136.	2.5	76
101	Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E532-E537.	3.5	74
102	Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2007, 47, 565-570.	3.7	73
103	Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3/TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. <i>Diabetologia</i> , 2013, 56, 2153-2163.	6.3	71
104	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. <i>EBioMedicine</i> , 2020, 52, 102658.	6.1	71
105	Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000904.	2.8	71
106	Insulin prolongs the QTc interval in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 279, R2022-R2025.	1.8	70
107	Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis. <i>Nature Communications</i> , 2019, 10, 2717.	12.8	70
108	Regulation of plasma fatty acid oxidation during low- and high-intensity exercise. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 272, E1065-E1070.	3.5	69

#	ARTICLE	IF	CITATIONS
109	Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. <i>Journal of Internal Medicine</i> , 2012, 271, 294-304.	6.0	68
110	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	7.3	67
111	Glucose kinetics during high-intensity exercise in endurance-trained and untrained humans. <i>Journal of Applied Physiology</i> , 1995, 78, 1203-1207.	2.5	66
112	The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 806-812.	3.6	64
113	Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women. <i>Fertility and Sterility</i> , 2007, 88, 1609-1617.	1.0	64
114	Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. <i>Diabetologia</i> , 2008, 51, 309-319.	6.3	63
115	Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery. <i>Scientific Reports</i> , 2017, 7, 9007.	3.3	62
116	Hydroxysteroid 17 β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. <i>JCI Insight</i> , 2020, 5, .	5.0	62
117	Quantification of Liver Glucose Metabolism by Positron Emission Tomography: Validation Study in Pigs. <i>Gastroenterology</i> , 2007, 132, 531-542.	1.3	61
118	Energy expenditure of swimmers during high volume training. <i>Medicine and Science in Sports and Exercise</i> , 1997, 29, 950-954.	0.4	60
119	Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. <i>Journal of Applied Physiology</i> , 1999, 87, 1813-1822.	2.5	58
120	Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 205-212.	4.7	58
121	Effects of Adding Exercise to a 16-Week Very Low-Calorie Diet in Obese, Insulin-Dependent Type 2 Diabetes Mellitus Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2512-2520.	3.6	57
122	Biliopancreatic Diversion in Nonobese Patients With Type 2 Diabetes: Impact and Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2765-2773.	3.6	57
123	Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. <i>Journal of Hypertension</i> , 2017, 35, 493-500.	0.5	57
124	Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. <i>Scientific Reports</i> , 2017, 7, 12200.	3.3	57
125	Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 153.e1-153.e9.	1.3	55
126	Glucokinase links KrÄppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1083-1093.	7.3	55

#	ARTICLE	IF	CITATIONS
127	Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk. <i>Diabetes Care</i> , 2013, 36, 3607-3612.	8.6	55
128	A model for glucose control of insulin secretion during 24 h of free living. <i>Diabetes</i> , 2001, 50, S164-S168.	0.6	53
129	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 393-403.	4.4	53
130	Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. <i>European Journal of Endocrinology</i> , 2013, 169, 421-430.	3.7	52
131	Increased FNDC5/Irisin expression in human hepatocellular carcinoma. <i>Peptides</i> , 2017, 88, 62-66.	2.4	52
132	Ectopic fat: the true culprit linking obesity and cardiovascular disease?. <i>Thrombosis and Haemostasis</i> , 2013, 110, 651-660.	3.4	51
133	PPAR β -induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. <i>Liver International</i> , 2021, 41, 2659-2670.	3.9	51
134	Matched weight loss induced by sleeve gastrectomy or gastric bypass similarly improves metabolic function in obese subjects. <i>Obesity</i> , 2014, 22, 2026-2031.	3.0	50
135	Visceral fat and beta cell function in non-diabetic humans. <i>Diabetologia</i> , 2005, 48, 2090-2096.	6.3	49
136	Women-specific predictors of cardiovascular disease risk - new paradigms. <i>International Journal of Cardiology</i> , 2019, 286, 190-197.	1.7	49
137	Fatty Liver Index Predicts Further Metabolic Deteriorations in Women with Previous Gestational Diabetes. <i>PLoS ONE</i> , 2012, 7, e32710.	2.5	49
138	Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. <i>Diabetologia</i> , 2000, 43, 1266-1272.	6.3	48
139	Protein synthesis and breakdown in skin and muscle: a leg model of amino acid kinetics. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1994, 267, E467-E474.	3.5	47
140	Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 194-202.	4.7	47
141	Relationship between fatty liver and glucose metabolism: A cross-sectional study in 571 obese children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 120-126.	2.6	47
142	Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance. <i>Diabetes</i> , 2021, 70, 377-385.	0.6	47
143	What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?. <i>Liver Transplantation</i> , 2011, 17, 633-640.	2.4	46
144	Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. <i>Diabetologia</i> , 2014, 57, 1199-1203.	6.3	46

#	ARTICLE	IF	CITATIONS
145	Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. <i>European Heart Journal</i> , 2008, 29, 386-393.	2.2	45
146	Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1763-1770.	3.6	45
147	Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. <i>Diabetes</i> , 2015, 64, 3406-3412.	0.6	45
148	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017, 40, 1530-1536.	8.6	45
149	Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. <i>Cytokine</i> , 2017, 99, 59-65.	3.2	45
150	The Effect of Menopause on Carotid Artery Remodeling, Insulin Sensitivity, and Plasma Adiponectin in Healthy Women. <i>American Journal of Hypertension</i> , 2009, 22, 364-370.	2.0	44
151	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 759-788.	4.5	44
152	Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108984.	2.8	43
153	Lipid and Carbohydrate Metabolism in IDDM During Moderate and Intense Exercise. <i>Diabetes</i> , 1995, 44, 1066-1074.	0.6	42
154	Effect of theophylline on substrate metabolism during exercise. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1153-1160.	3.4	42
155	Influence of duration of obesity on the insulin resistance of obese non-diabetic patients. <i>International Journal of Obesity</i> , 1998, 22, 262-267.	3.4	39
156	Influence of Ethnicity and Familial Diabetes on Glucose Tolerance and Insulin Action: A Physiological Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3251-3257.	3.6	39
157	Not all fats are created equal: adipose vs. ectopic fat, implication in cardiometabolic diseases. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2015, 22, 7-18.	0.7	39
158	Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5820.	4.1	38
159	Validation of [18F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity. <i>Diabetologia</i> , 2013, 56, 893-900.	6.3	37
160	Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis. <i>Diabetologia</i> , 2020, 63, 206-218.	6.3	37
161	Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk. <i>Current Pharmaceutical Design</i> , 2013, 19, 2420-2431.	1.9	37
162	Metabolic dysfunction-associated fatty liver disease: a year in review. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 251-260.	2.3	37

#	ARTICLE	IF	CITATIONS
163	Imaging cardiac fat. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 625-630.	1.2	36
164	Determination of the Enrichment of the Hydrogen Bound to Carbon 5 of Glucose on 2H2O Administration. <i>Analytical Biochemistry</i> , 2001, 297, 195-197.	2.4	35
165	Chrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2405-2414.	3.6	35
166	Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. <i>Diabetes Care</i> , 2016, 39, 1925-1931.	8.6	35
167	Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons. <i>Cardiovascular Diabetology</i> , 2009, 8, 22.	6.8	34
168	The Disposition Index Does Not Reflect β -Cell Function in IGT Subjects Treated With Pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3774-3781.	3.6	34
169	Fatty liver disease: the hepatic manifestation of metabolic syndrome. <i>Hypertension Research</i> , 2010, 33, 546-547.	2.7	33
170	Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study. <i>Journal of the Endocrine Society</i> , 2018, 2, 310-321.	0.2	33
171	Coordinated Defects in Hepatic Long Chain Fatty Acid Metabolism and Triglyceride Accumulation Contribute to Insulin Resistance in Non-Human Primates. <i>PLoS ONE</i> , 2011, 6, e27617.	2.5	33
172	¹⁸ F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1016-22.	5.0	33
173	Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk. <i>Current Pharmaceutical Design</i> , 2010, 16, 2526-2530.	1.9	32
174	The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF. <i>Scientific Reports</i> , 2018, 8, 1781.	3.3	32
175	Intra-abdominal adiposity, abdominal obesity, and cardiometabolic risk. <i>Country Review Ukraine</i> , 2008, 10, B4-B10.	0.8	30
176	Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. <i>Journal of Hepatology</i> , 2016, 64, 262-264.	3.7	30
177	Automatic correction of intensity inhomogeneities improves unsupervised assessment of abdominal fat by MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 403-410.	3.4	29
178	Peripheral Insulin Resistance and Impaired Insulin Signaling Contribute to Abnormal Glucose Metabolism in Preterm Baboons. <i>Endocrinology</i> , 2015, 156, 813-823.	2.8	29
179	Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity. <i>British Journal of Surgery</i> , 2019, 106, 1178-1186.	0.3	29
180	Protective role of adiponectin on endothelial dysfunction induced by AGEs: A clinical and experimental approach. <i>Microvascular Research</i> , 2011, 82, 73-76.	2.5	28

#	ARTICLE	IF	CITATIONS
181	Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E225-E230.	3.5	27
182	Insulin resistance, adipose depots and gut: Interactions and pathological implications. <i>Digestive and Liver Disease</i> , 2010, 42, 310-319.	0.9	27
183	The good and bad effects of statins on insulin sensitivity and secretion. <i>Endocrine Research</i> , 2014, 39, 137-143.	1.2	27
184	Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 105-114.	4.7	26
185	Comparison of Glargine Insulin Versus Rosiglitazone Addition in Poorly Controlled Type 2 Diabetic Patients on Metformin Plus Sulfonylurea. <i>Diabetes Care</i> , 2006, 29, 2371-2377.	8.6	26
186	Biomonitoring of Bis(2-ethylhexyl)phthalate (DEHP) in Italian children and adolescents: Data from LIFE PERSUADED project. <i>Environmental Research</i> , 2020, 185, 109428.	7.5	26
187	Î²-Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide. <i>Diabetes Care</i> , 2005, 28, 1132-1138.	8.6	25
188	Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans. <i>Diabetes</i> , 2018, 67, 1976-1985.	0.6	25
189	Inflammatory Biomarkers are Correlated with Some Forms of Regressive Autism Spectrum Disorder. <i>Brain Sciences</i> , 2019, 9, 366.	2.3	25
190	Relationship between hepatic and systemic angiotensin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. <i>Liver International</i> , 2020, 40, 2139-2147.	3.9	25
191	Characterization of Î² ² -cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E541-E546.	3.5	24
192	Effect of Oral Sebamic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2327-2332.	8.6	24
193	Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6333.	4.1	24
194	The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. <i>Current Opinion in Pharmacology</i> , 2020, 55, 165-174.	3.5	24
195	Metabolic, reproductive and thyroid effects of bis(2-ethylhexyl) phthalate (DEHP) orally administered to male and female juvenile rats at dose levels derived from children biomonitoring study. <i>Toxicology</i> , 2021, 449, 152653.	4.2	24
196	Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of nonalcoholic steatohepatitis. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13695.	3.4	24
197	Metabolic Consequences of Adipose Triglyceride Lipase Deficiency in Humans: An In Vivo Study in Patients With Neutral Lipid Storage Disease With Myopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1540-E1548.	3.6	23
198	Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study. <i>Journal of Diabetes Investigation</i> , 2015, 6, 164-172.	2.4	23

#	ARTICLE	IF	CITATIONS
199	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. <i>BMC Gastroenterology</i> , 2018, 18, 177.	2.0	23
200	The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake. <i>EBioMedicine</i> , 2019, 46, 368-380.	6.1	23
201	Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity. <i>Nutrients</i> , 2021, 13, 437.	4.1	23
202	Abdominal fat: does it predict the development of type 2 diabetes?. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1118-1119.	4.7	22
203	Ectopic Fat Storage, Insulin Resistance, and Hypertension. <i>Current Pharmaceutical Design</i> , 2011, 17, 3074-3080.	1.9	22
204	The role of cardiac fat in insulin resistance. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2012, 15, 523-528.	2.5	22
205	The effect of chronic twice daily exenatide treatment on β -cell function in new onset type 2 diabetes. <i>Clinical Endocrinology</i> , 2014, 80, 545-553.	2.4	22
206	An extended fatty liver index to predict non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2017, 43, 229-239.	2.9	22
207	Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 369-377.	4.7	22
208	Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8838.	4.1	22
209	Elevated Concentrations of Liver Enzymes and Ferritin Identify a New Phenotype of Insulin Resistance: Effect of Weight Loss After Gastric Banding. <i>Obesity Surgery</i> , 2009, 19, 80-86.	2.1	21
210	Hepatic fat is not associated with β -cell function or postprandial free fatty acid response. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 196-203.	3.4	21
211	Liver-targeting drugs and their effect on blood glucose and hepatic lipids. <i>Diabetologia</i> , 2021, 64, 1461-1479.	6.3	21
212	Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. <i>European Journal of Endocrinology</i> , 2009, 161, 223-230.	3.7	20
213	The ontogeny of the endocrine pancreas in the fetal/newborn baboon. <i>Journal of Endocrinology</i> , 2012, 214, 289-299.	2.6	20
214	Insulin sensitivity depends on the route of glucose administration. <i>Diabetologia</i> , 2020, 63, 1382-1395.	6.3	20
215	Hepatic and Cardiac Steatosis. <i>Heart Failure Clinics</i> , 2012, 8, 663-670.	2.1	19
216	Metabolic response to high-carbohydrate and low-carbohydrate meals in a nonhuman primate model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E444-E451.	3.5	19

#	ARTICLE	IF	CITATIONS
217	Beta-cell sensitivity to glucose is impaired after gastric bypass surgery. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 872-878.	4.4	19
218	Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 106-113.	2.6	19
219	Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2001178.	3.3	19
220	Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?. <i>Annals of Hepatology</i> , 2020, 19, 380-387.	1.5	19
221	Angiopietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7197.	4.1	19
222	[11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia. <i>Nuclear Medicine and Biology</i> , 2006, 33, 521-528.	0.6	18
223	Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 434-443.	3.4	18
224	Small intestinal metabolism is central to whole-body insulin resistance. <i>Gut</i> , 2021, 70, 1098-1109.	12.1	18
225	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. <i>World Journal of Hepatology</i> , 2018, 10, 231-245.	2.0	18
226	Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. <i>Computer Methods and Programs in Biomedicine</i> , 2008, 89, 132-140.	4.7	17
227	Glucose kinetics. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2017, 20, 300-309.	2.5	17
228	The PNPLA3 ϵ 148M variant increases polyunsaturated triglycerides in human adipose tissue. <i>Liver International</i> , 2020, 40, 2128-2138.	3.9	17
229	Mastiha has efficacy in immune-mediated inflammatory diseases through a microRNA-155 Th17 dependent action. <i>Pharmacological Research</i> , 2021, 171, 105753.	7.1	17
230	Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction. <i>Atherosclerosis</i> , 2013, 229, 277-281.	0.8	16
231	Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion. <i>Diabetologia</i> , 2014, 57, 1495-1499.	6.3	16
232	The LIFE PERSUADED project approach on phthalates and bisphenol A biomonitoring in Italian mother-child pairs linking exposure and juvenile diseases. <i>Environmental Science and Pollution Research</i> , 2018, 25, 25618-25625.	5.3	16
233	Older Subjects With β -Cell Dysfunction Have an Accentuated Incretin Release. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2613-2619.	3.6	16
234	Phthalates Exposure as Determinant of Albuminuria in Subjects With Type 2 Diabetes: A Cross-Sectional Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1491-1499.	3.6	16

#	ARTICLE	IF	CITATIONS
235	Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery. <i>Gut</i> , 2019, 68, 1838-1845.	12.1	16
236	New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms. <i>Diabetes Care</i> , 2021, 44, 2115-2123.	8.6	16
237	Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition. <i>Diabetes Care</i> , 2021, 44, 541-548.	8.6	16
238	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146TCF7L2Gene Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1160-E1167.	3.6	15
239	Effect of exenatide on postprandial glucose fluxes, lipolysis, and β -cell function in non-diabetic, morbidly obese patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 412-420.	4.4	15
240	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069.	8.6	15
241	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. <i>Diabetes</i> , 2021, 70, 204-213.	0.6	15
242	External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 520.	2.4	15
243	Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon <i>Papio hamadryas</i> . <i>JCI Insight</i> , 2019, 4, .	5.0	15
244	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (<sc>EDICT</sc>). <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 899-907.	4.4	15
245	Obesity and carotid artery remodeling. <i>Nutrition and Diabetes</i> , 2015, 5, e177-e177.	3.2	14
246	Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A "non-invasive alternative" to liver biopsy?. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154010.	3.4	14
247	Fatty liver, cardiometabolic disease and mortality. <i>Current Opinion in Lipidology</i> , 2020, 31, 27-31.	2.7	14
248	Toxicological Assessment of Oral Co-Exposure to Bisphenol A (BPA) and Bis(2-ethylhexyl) Phthalate (DEHP) in Juvenile Rats at Environmentally Relevant Dose Levels: Evaluation of the Synergic, Additive or Antagonistic Effects. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4584.	2.6	14
249	Regulation of glucose production during exercise at 80% of VO ₂ peak in untrained humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E348-E354.	3.5	13
250	ORIGINAL ARTICLE: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study. <i>Clinical Endocrinology</i> , 2010, 73, 339-345.	2.4	13
251	Metabolic effects of muraglitazar in type 2 diabetic subjects. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 893-902.	4.4	13
252	Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1019-1026.	3.3	13

#	ARTICLE	IF	CITATIONS
253	Eight weeks of treatment with long-acting GLP-1 analog tasoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1330-1339.	3.4	12
254	Aleglitazar, a dual peroxisome proliferator-activated receptor- α/β agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 711-715.	4.4	12
255	Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD. <i>Frontiers in Immunology</i> , 2021, 12, 683028.	4.8	12
256	Lipid and carbohydrate metabolism in IDDM during moderate and intense exercise. <i>Diabetes</i> , 1995, 44, 1066-1074.	0.6	12
257	Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 635.	2.4	12
258	Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy. <i>Metabolism: Clinical and Experimental</i> , 2022, 131, 155199.	3.4	12
259	Glucose kinetics in interstitial fluid can be predicted by compartmental modeling. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 272, E494-E505.	3.5	11
260	Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW. <i>Diabetes Care</i> , 2014, 37, 1706-1711.	8.6	11
261	Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 739-744.	3.3	11
262	Chronic Intranasal Insulin Does Not Affect Hepatic Lipids but Lowers Circulating BCAAs in Healthy Male Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1325-1332.	3.6	11
263	An extra virgin olive oil-enriched chocolate spread positively modulates insulin-resistance markers compared with a palm oil-enriched one in healthy young adults: A double-blind, crossover, randomised controlled trial. <i>Diabetes/Metabolism Research and Reviews</i> , 2022, 38, e3492.	4.0	11
264	Assessment of Exposure to Di-(2-ethylhexyl) Phthalate (DEHP) Metabolites and Bisphenol A (BPA) and Its Importance for the Prevention of Cardiometabolic Diseases. <i>Metabolites</i> , 2022, 12, 167.	2.9	11
265	Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. <i>Diabetes and Metabolism</i> , 2022, 48, 101363.	2.9	11
266	Kinetic Analysis and Comparison of Models of Xylose Metabolism by <i>Klebsiella planticola</i> . <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 41-46.	2.1	10
267	Modeling Interpretation of Microbe Metabolism Detected by Nuclear Magnetic Resonance. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 53-58.	2.1	10
268	Effects of acute β_2 -blockade on insulin action and secretion in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 274, E57-E64.	3.5	10
269	Imaging and Laboratory Biomarkers in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2009, 15, 1131-1141.	1.9	9
270	Early effect of Roux-en-Y gastric bypass on insulin sensitivity and signaling. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 42-47.	1.2	9

#	ARTICLE	IF	CITATIONS
271	Hepatic Insulin Resistance and Altered Gluconeogenic Pathway in Premature Baboons. <i>Endocrinology</i> , 2017, 158, 1140-1151.	2.8	9
272	Juvenile Toxicity Rodent Model to Study Toxicological Effects of Bisphenol A (BPA) at Dose Levels Derived From Italian Children Biomonitoring Study. <i>Toxicological Sciences</i> , 2020, 173, 387-401.	3.1	9
273	Mechanisms for increased risk of diabetes in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2489-2499.	3.9	9
274	SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial. <i>Environmental Research</i> , 2021, 192, 110316.	7.5	9
275	A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once) vs. liraglutide daily in obese subjects. <i>Obesity and Metabolism</i> , 2014, 16, 170-178.	4.4	8
276	Ectopic fat: a target for cardiometabolic risk management. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1301-1303.	1.5	8
277	Role of vagal activation in postprandial glucose metabolism after gastric bypass in individuals with and without hypoglycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1513-1517.	4.4	8
278	Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction. <i>Handbook of Experimental Pharmacology</i> , 2022, , 145-164.	1.8	8
279	Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7667.	4.1	8
280	A modellistic view of the kinetics of metabolic processes: differences in the glucose and xylose degradation pathway. <i>Chemical Physics Letters</i> , 1999, 310, 38-42.	2.6	7
281	The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle <i>in vivo</i> . <i>Diabetic Medicine</i> , 2015, 32, 657-664.	2.3	7
282	Glucose uptake saturation explains glucose kinetics profiles measured by different tests. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 311, E346-E357.	3.5	7
283	The color of fat and its central role in the development and progression of metabolic diseases. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 31, .	0.7	7
284	Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. <i>Endocrine</i> , 2020, 67, 569-578.	2.3	7
285	Albiglutide for the treatment of type 2 diabetes mellitus. <i>Drugs of Today</i> , 2014, 50, 665.	1.1	7
286	Italian Children Exposure to Bisphenol A: Biomonitoring Data from the LIFE PERSUADED Project. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11846.	2.6	7
287	Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. <i>Diabetologia</i> 43:317-39. <i>Diabetologia</i> , 2004, 47, 1643-1644.	6.3	6
288	A Pilot Randomised Study of the Metabolic and Histological Effects of Exercise in Non-alcoholic Steatohepatitis. <i>Journal of Diabetes & Metabolism</i> , 2013, 04, .	0.2	6

#	ARTICLE	IF	CITATIONS
289	Linear and Nonlinear Properties of Heart Rate Variability: Influence of Obesity. <i>Annals of the New York Academy of Sciences</i> , 1999, 879, 249-254.	3.8	5
290	A model for assessing insulin secretion and its control under free-living conditions. <i>Diabetes</i> , 2001, 50, S178-S179.	0.6	5
291	Diet and Exercise in the Treatment of Fatty Liver. <i>Journal of Nutrition and Metabolism</i> , 2012, 2012, 1-2.	1.8	5
292	Biomarkers of exposure and early effect in three contaminated sites of southern Italy: protocols for etiological epidemiological studies. <i>BMJ Open</i> , 2020, 10, e036160.	1.9	5
293	Changes in Plasma Bioactive Lipids and Inflammatory Markers during a Half-Marathon in Trained Athletes. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4622.	2.5	4
294	Metabolite Changes After Metabolic Surgery – Associations to Parameters Reflecting Glucose Homeostasis and Lipid Levels. <i>Frontiers in Endocrinology</i> , 2021, 12, 786952.	3.5	4
295	re: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. <i>Diabetologia</i> 47:31739. <i>Diabetologia</i> , 2004, 47, 1642-1643.	6.3	3
296	Diabetes and Nonalcoholic Fatty Liver Disease. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-2.	3.8	3
297	1290 THE EFFECT OF EXERCISE ON THE METABOLIC AND HISTOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2012, 56, S509.	3.7	3
298	Motor Activity in Aging: An Integrated Approach for Better Quality of Life. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-9.	0.9	3
299	Saturated fat is more metabolically harmful for the human liver than polyunsaturated fat or simple sugars. <i>Journal of Hepatology</i> , 2018, 68, S836.	3.7	3
300	Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4230.	4.1	3
301	COVID-19 Infection Pandemic: From the Frontline in Italy. <i>Journal of the American College of Nutrition</i> , 2020, 39, 677-684.	1.8	3
302	Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. <i>Diabetes Care</i> 2020;43:2296–2302. <i>Diabetes Care</i> , 2021, 44, e98-e99.	8.6	3
303	Assessment of RANKL/RANK/osteoprotegerin system expression in patients with hepatocellular carcinoma. <i>Minerva Endocrinology</i> , 0, , .	1.1	3
304	Impact of percent body fat on oral glucose tolerance testing: a cross-sectional study in 1512 obese children. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 893-6.	3.3	3
305	A new approach to study in vivo cellular metabolism using a modellistic analysis of magnetic resonance spectra. <i>Mathematical Biosciences</i> , 2009, 222, 36-41.	1.9	2
306	Integrated Physiology/Obesity. <i>Diabetes</i> , 2012, 61, A443-A522.	0.6	2

#	ARTICLE	IF	CITATIONS
307	The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and non-alcoholic fatty liver disease progression in mice lacking NLRP3-inflammasome. <i>Journal of Hepatology</i> , 2017, 66, S16.	3.7	2
308	Bile acid composition modulates insulin resistance in non-diabetic patients with NAFLD. <i>Digestive and Liver Disease</i> , 2018, 50, 17.	0.9	2
309	Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, <i>Papio sp.</i> . <i>PLoS ONE</i> , 2018, 13, e0208757.	2.5	2
310	Healthy aging: the INTECMAN project. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2011-2015.	2.9	2
311	The <i>Pro12Ala</i> polymorphism of <i>PPARβ</i> modulates beta cell function and failure to oral glucose-lowering drugs in patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3392.	4.0	2
312	Association of serum lipids with β -cell function in obese children and adolescents. <i>Endocrine Connections</i> , 2019, 8, 1318-1323.	1.9	2
313	Beneficial Effects of RYGB on β -Cell Function and Hepatic and Peripheral Insulin Sensitivity Are Maintained Seven Years after Surgery in Both Diabetic and Nondiabetic Subjects. <i>Diabetes</i> , 2018, 67, 2089-P.	0.6	2
314	Pathophysiology of Prediabetes: Role of Lipotoxicity?. , 2014, , 31-47.		2
315	Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 971.	2.6	2
316	60 Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis. <i>Journal of Hepatology</i> , 2004, 40, 21.	3.7	1
317	55 METABOLIC AND ANTI-INFLAMMATORY BENEFICIAL EFFECTS OF PIOGLITAZONE (PIO) TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND THEIR ASSOCIATIONS WITH HISTOLOGICAL IMPROVEMENT. <i>Journal of Hepatology</i> , 2009, 50, S24.	3.7	1
318	P840 ALTERATION IN LIPID METABOLISM AFTER AN ORAL FAT LOAD IN PATIENTS WITH NAFLD. <i>Journal of Hepatology</i> , 2014, 60, S352.	3.7	1
319	Brown versus white fat: are they really playing a role in obesity and cardiometabolic risk?. <i>Clinical Lipidology</i> , 2015, 10, 365-368.	0.4	1
320	Neurophysiological and Behavioural Variables in Cognitive Impairment: Towards a Personalised Monitoring System. <i>Biosystems and Biorobotics</i> , 2015, , 407-417.	0.3	1
321	Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, e12.	0.9	1
322	Lack of NLRP3-Inflammasome Leads to Gut-Liver AXIS Derangement and Increases Hepatic Injury in a Mouse Model of Non-Alcoholic Fatty Liver Disease. <i>Journal of Hepatology</i> , 2016, 64, S679.	3.7	1
323	Increased hepatic glucose production and insulin resistance are associated to increased plasma concentrations of glucogenic amino acids in subjects with NAFLD. <i>Digestive and Liver Disease</i> , 2017, 49, e1.	0.9	1
324	Predisposition to diabetes is related to insulin resistance in NAFLD patients and to decreased insulin secretion in HCV patients. <i>Journal of Hepatology</i> , 2018, 68, S835.	3.7	1

#	ARTICLE	IF	CITATIONS
325	Bile acid composition modulate insulin resistance in non-diabetic patients with NAFLD. <i>Journal of Hepatology</i> , 2018, 68, S338.	3.7	1
326	TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. <i>Digestive and Liver Disease</i> , 2021, 53, S27-S28.	0.9	1
327	NAFLD and Insulin Resistance: A Multisystemic Disease. , 2020, , 49-71.		1
328	White and Brown Adipose Tissue Development. , 2014, , 237-246.		1
329	Assessment of RANKL/RANK/osteoprotegerin system expression in patients with hepatocellular carcinoma. <i>Minerva Endocrinology</i> , 2021, 46, 367-369.	1.1	1
330	245-OR: Glucose Production and Utilization following Oral Glucose Load in Type 2 Diabetes Patients Treated with Dapagliflozin Alone and in Saxagliptin Combination. <i>Diabetes</i> , 2019, 68, 245-OR.	0.6	1
331	Disparity-filtered differential correlation network analysis: a case study on CRC metabolomics. <i>Journal of Integrative Bioinformatics</i> , 2021, 18, .	1.5	1
332	Validation of Tracer Estimations of Plasma Free Fatty Acid Oxidation. <i>Clinical Science</i> , 1994, 87, 94-95.	0.0	0
333	Changes in Tracer Infusion Rates to Minimize the Structure Error in the Steele's Model. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 281-282.	0.4	0
334	An Energy Model for the Description of a Metabolic Process. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 377-378.	0.4	0
335	A Leg Model of Amino Acid Kinetics in Skin and Muscle. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 391-393.	0.4	0
336	Pathway of Free Fatty Acid Oxidation. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 413-414.	0.4	0
337	850 PATHWAY OF PLASMA FFA OXIDATION DURING EXERCISE. <i>Medicine and Science in Sports and Exercise</i> , 1994, 26, S152.	0.4	0
338	A Model for Assessing Insulin Secretion Function During a 24 Hour Standardized Life Period. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2000, 33, 35-40.	0.4	0
339	O-210. <i>Fertility and Sterility</i> , 2006, 86, S90.	1.0	0
340	Pathogenesis and Clinical Features of Obesity and Insulin Resistance. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2006, 6, 81-89.	0.5	0
341	ANALYSIS OF DOUBLE-TRACER GLUCOSE KINETICS IN HUMANS DURING ORAL GLUCOSE TOLERANCE TEST. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2006, 39, 57-62.	0.4	0
342	36 FATTY LIVER INDEX IS ASSOCIATED WITH INCREASED INSULIN RESISTANCE AND CAROTID INTIMA MEDIA THICKNESS (IMT) IN NONDIABETIC SUBJECTS: THE RISC STUDY. <i>Journal of Hepatology</i> , 2008, 48, S16.	3.7	0

#	ARTICLE	IF	CITATIONS
343	Reply:. Hepatology, 2009, 50, 989-990.	7.3	0
344	346 INCREASED LIVER EXPRESSION OF INFLAMMATORY MEDIATORS IS ASSOCIATED WITH HEPATIC INSULIN RESISTANCE IN LEAN, NON-DIABETIC PATIENTS WITH CHRONIC HEPATITIS C. Journal of Hepatology, 2009, 50, S133.	3.7	0
345	82 KRUPPEL LIKE FACTOR 6 (KLF6) REGULATES HEAPTIC INSULIN RESISTANCE (HEP-IR). Journal of Hepatology, 2010, 52, S37.	3.7	0
346	340 FATTY LIVER INDEX (FLI) IS AN INDEPENDENT PREDICTOR OF CHANGES IN METABOLIC AND CARDIOVASCULAR PARAMETERS: RESULTS FROM A 3-YEAR FOLLOW UP IN THE RISC STUDY. Journal of Hepatology, 2010, 52, S142.	3.7	0
347	1264 CRITICAL ROLE OF TRIGLYCERIDES AND LONG CHAIN FATTY ACYL COA ACCUMULATION IN LIVER INSULIN RESISTANCE IN THE BABOON. A NEW NON-HUMAN PRIMATE MODEL OF NAFLD. Journal of Hepatology, 2011, 54, S499.	3.7	0
348	842 PREDISPOSITION TO DEVELOP DIABETES IN SUBJECTS WITH NAFLD IS RELATED TO INSULIN RESISTANCE RATHER THAN TO DECREASED B-CELL FUNCTION. Journal of Hepatology, 2011, 54, S336-S337.	3.7	0
349	Dynamics of Circulating Ligands and Soluble Receptor for Advanced Glycation End-Product in Liver Transplantation. Transplantation, 2012, 94, 305.	1.0	0
350	Dynamics of Circulating Ligands and Soluble Receptor for Advanced Glycation End-Product in Liver Transplantation. Transplantation, 2012, 94, 653.	1.0	0
351	215 THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (RAGE) AXIS IN LIVER TRANSPLANTATION. Journal of Hepatology, 2012, 56, S91.	3.7	0
352	1310 PERIPHERAL INSULIN RESISTANCE RATHER THAN HEPATIC IS A PRIMARY DEFECT IN NON OBESE, NON DIABETIC, NON DYSLIPIDEMIC NAFLD PATIENTS: CORRELATION WITH LIVER DAMAGE. Journal of Hepatology, 2012, 56, S516.	3.7	0
353	1351 CONTRIBUTION OF VISCERAL FAT AND HEPATIC FAT TO METABOLIC DERANGEMENTS AND LIVER DAMAGE IN NAFLD PATIENTS. Journal of Hepatology, 2013, 58, S543-S544.	3.7	0
354	73 KR ÅœPPEL LIKE FACTOR 6 (KLF6) PROTECTS FROM NAFLD PROGRESSION THROUGH REGULATION OF ADIPOSE TISSUE INSULIN RESISTANCE. Journal of Hepatology, 2013, 58, S33.	3.7	0
355	1365 METABOLIC ALTERATIONS OF LIPID KINETICS IN NAFLD PATIENTS AND THEIR CONTRIBUTION TO LIVER DAMAGE. Journal of Hepatology, 2013, 58, S549.	3.7	0
356	Corrigendum to â€œInsulin resistance, adipose depots and gut: Interactions and pathological implicationsâ€•[Dig. Liver Dis. 42 (2010) 310â€“319]. Digestive and Liver Disease, 2014, 46, 1055.	0.9	0
357	P843 ALTERATION IN GLUCOSE METABOLISM AFTER AN ORAL GLUCOSE LOAD AND RELATIONSHIP WITH LIVER DAMAGE IN PATIENTS WITH NAFLD. Journal of Hepatology, 2014, 60, S352-S353.	3.7	0
358	P857 A NEW INDEX OF GLUTATHIONE TURNOVER (GSH_TI) AND ITS ASSOCIATION WITH SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Journal of Hepatology, 2014, 60, S357-S358.	3.7	0
359	Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2014, 46, e54.	0.9	0
360	P849 QUANTITATIVE AND QUALITATIVE ANALYSIS OF PLASMA FREE FATTY ACIDS AND THEIR IMPACT ON LIVER DAMAGE IN NAFLD PATIENTS. Journal of Hepatology, 2014, 60, S354-S355.	3.7	0

#	ARTICLE	IF	CITATIONS
361	Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2014, 46, e53-e54.	0.9	0
362	Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2014, 46, e54.	0.9	0
363	P845 IMPACT OF FAT VERSUS GLUCOSE LOAD ON OXIDATIVE STRESS IN NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S353.	3.7	0
364	Gut-liver axis derangement due to lack of inflammasome activity leads to visceral obesity and NASH development. <i>Digestive and Liver Disease</i> , 2015, 47, e4.	0.9	0
365	Liver damage can be associated with deregulation of the de novo lipogenesis pathway in subjects with Non Alcoholic Fatty Liver Disease. <i>Digestive and Liver Disease</i> , 2015, 47, e5.	0.9	0
366	O064 : Gut-liver axis derangement due to lack of inflammasome activity leads to visceral obesity and nash development. <i>Journal of Hepatology</i> , 2015, 62, S223.	3.7	0
367	P0519 : Lipidomics reveals that low plasma unsaturated to saturated fat ratios are biomarkers of NAFLD and liver damage. <i>Journal of Hepatology</i> , 2015, 62, S509.	3.7	0
368	P1056 : Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in patients with nonalcoholic fatty liver disease, independently of diabetes, hypertension and dyslipidemia. <i>Journal of Hepatology</i> , 2015, 62, S744-S745.	3.7	0
369	P1042 : Deregulation of de novo lipogenesis can be associated with liver damage in patients with non alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 62, S738.	3.7	0
370	Lack of NLRP3-inflammasome leads to gut-liver axis derangement and increases hepatic injury in a mouse model of NAFLD. <i>Digestive and Liver Disease</i> , 2016, 48, e9-e10.	0.9	0
371	Angiotensin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, e38.	0.9	0
372	Exenatide Exerts Its Positive Effects on Liver by Reducing both Hepatic and Adipose Tissue Insulin Resistance. <i>Journal of Hepatology</i> , 2016, 64, S171.	3.7	0
373	Evaluation of Metabolic Parameters of Hepatic Dysfunction in Subjects with Hepatocellular Carcinoma and their Change after Liver Transplantation: A Metabolomic Approach. <i>Journal of Hepatology</i> , 2016, 64, S316.	3.7	0
374	Angiotensin-Like4 is Associated with Lipid Metabolism and Severe Fibrosis in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Hepatology</i> , 2016, 64, S477.	3.7	0
375	Adipose Tissue Insulin Resistance is Associated with Macrophage Activation in Non-Diabetic Patients with Non-Alcoholic Fatty Liver Disease. <i>Journal of Hepatology</i> , 2016, 64, S476.	3.7	0
376	Response to: Drug therapy for ectopic fat: myth or reality?. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 73-74.	1.5	0
377	Novel hepato-preferential basal insulin peglispro (<sc>BIL</sc>) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 482-488.	4.4	0
378	The combination of mucus-degrading gram-negative bacteria and reduced antimicrobial peptides drives adipose tissue inflammation and NAFLD progression in mice lacking NLRP3-inflammasome. <i>Digestive and Liver Disease</i> , 2017, 49, e2-e3.	0.9	0

#	ARTICLE	IF	CITATIONS
379	Response to Comment on Gastaldelli et al. Short-term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass. <i>Diabetes Care</i> 2016;39:1925-1931. <i>Diabetes Care</i> , 2017, 40, e50-e50.	8.6	0
380	Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids. <i>Journal of Hepatology</i> , 2017, 66, S163.	3.7	0
381	P.09.3 LACK OF NLRP3-INFLAMMASOME LEADS TO GLUT-LIVER AXIS DERANGEMENT, GLUT DYSBIOSIS AND A WORSENER PHENOTYPE IN A MOUSE MODEL OF NAFLD. <i>Digestive and Liver Disease</i> , 2018, 50, e217.	0.9	0
382	Reply. <i>Hepatology</i> , 2018, 67, 1178-1180.	7.3	0
383	In non obese NAFLD increased plasma saturated fatty acids and insulin resistance are metabolic signatures of severity of liver disease. <i>Journal of Hepatology</i> , 2018, 68, S566.	3.7	0
384	Impact of short term weight loss (very low calorie diet vs bariatric surgery) on hepatic insulin resistance and plasma lipidomic profile. <i>Journal of Hepatology</i> , 2018, 68, S817.	3.7	0
385	PS-006-MBOAT7 downregulation induces hepatic lipid accumulation. <i>Journal of Hepatology</i> , 2019, 70, e8.	3.7	0
386	SAT-323-Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 70, e782.	3.7	0
387	FRI-283-Impact on NAFLD of long-term weight loss after bariatric surgery. <i>Journal of Hepatology</i> , 2019, 70, e520.	3.7	0
388	Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet. <i>Digestive and Liver Disease</i> , 2019, 51, e30.	0.9	0
389	SAT-290-Association of liver inflammation and fibrosis score with noninvasive biomarkers in non-alcoholic fatty liver disease: Preliminary results from the MAST4HEALTH study. <i>Journal of Hepatology</i> , 2019, 70, e765.	3.7	0
390	Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, e26.	0.9	0
391	27th Annual Meeting of the European Group for the study of Insulin Resistance, Lisbon, Portugal, 8-9th May 2019. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019, 8, 88-89.	1.1	0
392	Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2020, 52, e10.	0.9	0
393	Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk. <i>Journal of Human Hypertension</i> , 2021, 35, 334-342.	2.2	0
394	Modelling Interpretation of the Kinetics of Metabolic Processes. , 2000, , 305-328.		0
395	Importance of liver fat indices for diagnosis of hepatic steatosis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, .	1.2	0
396	Lean Subjects with Fatty Liver Show Decreased GLP-1 and GIP Response during OGTT. <i>Diabetes</i> , 2018, 67, 1869-P.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Reduced insulin clearance relates to increased liver fat content in recent-onset type 2 diabetes and to impaired glucose control in recent-onset type 1 diabetes. , 2019, 14, .		0
398	1888-P: Impaired Insulin Clearance Relates to Increased Liver Fat Content in Recent-Onset Type 2 Diabetes and to Impaired Glucose Control in Recent-Onset Type 1 Diabetes. Diabetes, 2019, 68, .	0.6	0
399	1840-P: Pioglitazone Increases Metabolic Insulin Clearance (MCRI) in IGT Subjects: The ACT NOW Study. Diabetes, 2019, 68, .	0.6	0
400	155-LB: The Increase in Endogenous Glucose Production with SGLT2 Inhibition Is Unchanged by Renal Denervation but Highly Correlates to Urinary Glucose Excretion. Diabetes, 2019, 68, .	0.6	0
401	Reduced insulin clearance relates to increased liver fat content in recent-onset type 2 diabetes and to impaired glucose control in recent-onset type 1 diabetes. Endocrine Abstracts, 0, , .	0.0	0
402	1774-P: Neurally Mediated Prandial Islet-Cell Function Is Glucose-Independent and Preserved after Gastric Bypass and Sleeve Gastrectomy. Diabetes, 2020, 69, .	0.6	0
403	352-OR: Combination Therapy with Dapagliflozin plus Exenatide on Endogenous Glucose Production: A Mechanism of Action Study. Diabetes, 2020, 69, 352-OR.	0.6	0
404	153-OR: Glucose-Dependency of Insulinotropic and Glucagonostatic Effects of Glucagon-Like Peptide-1 after Gastric Bypass and Sleeve Gastrectomy. Diabetes, 2020, 69, 153-OR.	0.6	0
405	1836-P: Nonalcoholic Steatohepatitis (NASH) Significantly Contribute to β -Cell Function Impairment Independently of Glucose Tolerance Status. Diabetes, 2020, 69, .	0.6	0
406	Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. Clinical and Experimental Rheumatology, 2019, 37, 1036-1043.	0.8	0
407	Editorial: Mechanisms for the Alteration in the Crosstalk Among Insulin-Sensitive Tissues. Frontiers in Endocrinology, 2022, 13, 883659.	3.5	0